Boundless Bio, Inc. entered into a merger agreement with Serapha Bio, Inc. to undergo a reorganization, with Serapha equityholders expected to own approximately 96.31% of the combined company. The transaction includes a potential pre-closing cash dividend and a planned reverse stock split. Boundless Bio also announced a 75% workforce reduction with expected costs between $3.0 million and $5.0 million. Boundless Bio is a biotechnology company focused on developing therapeutic solutions for genetic diseases.